Measured Wealth Private Client Group LLC boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 447.1% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,019 shares of the biopharmaceutical company’s stock after acquiring an additional 21,263 shares during the quarter. Bristol-Myers Squibb accounts for about 0.9% of Measured Wealth Private Client Group LLC’s investment portfolio, making the stock its 24th largest position. Measured Wealth Private Client Group LLC’s holdings in Bristol-Myers Squibb were worth $1,319,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Lodestar Investment Counsel LLC IL boosted its holdings in Bristol-Myers Squibb by 5.2% during the 2nd quarter. Lodestar Investment Counsel LLC IL now owns 113,720 shares of the biopharmaceutical company’s stock valued at $5,157,000 after acquiring an additional 5,579 shares during the period. Perella Weinberg Partners Capital Management LP boosted its holdings in Bristol-Myers Squibb by 10.9% during the 1st quarter. Perella Weinberg Partners Capital Management LP now owns 19,431 shares of the biopharmaceutical company’s stock valued at $99,000 after acquiring an additional 1,905 shares during the period. Cypress Capital Management LLC boosted its holdings in Bristol-Myers Squibb by 21.2% during the 2nd quarter. Cypress Capital Management LLC now owns 154,335 shares of the biopharmaceutical company’s stock valued at $6,999,000 after acquiring an additional 26,990 shares during the period. Nachman Norwood & Parrott Inc boosted its holdings in Bristol-Myers Squibb by 3.5% during the 2nd quarter. Nachman Norwood & Parrott Inc now owns 50,388 shares of the biopharmaceutical company’s stock valued at $2,285,000 after acquiring an additional 1,687 shares during the period. Finally, Edge Wealth Management LLC boosted its holdings in Bristol-Myers Squibb by 217.7% during the 2nd quarter. Edge Wealth Management LLC now owns 10,007 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 6,857 shares during the period. Institutional investors and hedge funds own 80.17% of the company’s stock.
In other news, Director Robert J. Bertolini bought 11,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.
Shares of NYSE:BMY traded up $1.05 during trading on Friday, hitting $51.83. The stock had a trading volume of 412,078 shares, compared to its average volume of 9,791,409. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $60.77. The company has a market capitalization of $82.38 billion, a PE ratio of 12.98, a PEG ratio of 2.48 and a beta of 0.72. The firm’s fifty day moving average is $49.24 and its 200 day moving average is $47.03. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The firm had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same quarter in the prior year, the company earned $1.01 EPS. The business’s revenue was up 10.0% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb Co will post 4.29 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
Several equities research analysts recently weighed in on the company. Bank of America increased their target price on Bristol-Myers Squibb from $49.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a report on Wednesday, August 14th. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. UBS Group dropped their target price on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a report on Thursday, June 13th. Finally, JPMorgan Chase & Co. set a $62.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, September 13th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $55.81.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: Asset Allocation
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.